Preeclampsia and Defective Placentation in Oocyte Donation: Importance of HLA-C and KIR

NCT ID: NCT07178652

Last Updated: 2025-09-17

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 2325 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-09-30
• Study Completion Date: 2029-08-31

Brief Summary

The IMMUN-OR study aims to study HLA-C/KIR combinations when looking at the risk of development of preeclampsia (PE) in pregnancies after oocyte donation. With the use of oocyte donation currently on the rise, the importance of identifying risk factors for the higher frequency of PE development is clear. Certain HLA-C/KIR combinations have already been linked to higher risk of obstetric complications. This study will look at these combinations within the specific situation of oocyte donation. This will further investigate the importance of the immunological interface when looking at PE. Participants will be chosen from a database of all the live births after oocyte donation at our center. The research team will contact the mother, child and donor. If all three agree to participate, they will be invited to our center, where the research team will take a cheek swab. This swab will then be used to isolate a DNA sample. With these samples, we can determine the HLA-C/KIR combination for each threesome. When all samples have been collected, two groups are made based off their health outcome: one group that did develop PE during their pregnancy, and one group that did not develop PE. The different HLA-C/KIR combinations will be compared, and the research team will look to discover if one combination is linked to a higher occurrence of PE development.

Conditions

Preeclampsia (PE) Risk; Oocyte Donation

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

PE

Patients who develop PE during their pregnancy after oocyte donation.

No interventions assigned to this group

No PE

Patients who do not develop PE during their pregnancy after oocyte donation.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Every live birth delivery post oocyte donation (mother, child, donor).

Exclusion Criteria

• Unknown HLA-C/KIR typing of acceptor, donor or offspring (resumlts of all 3 parties must be present to participate.

• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Universitair Ziekenhuis Brussel

OTHER

Sponsor Role: lead

Responsible Party

Neelke De Munck

Head of the ART lab

Responsibility Role: PRINCIPAL_INVESTIGATOR

Other Identifiers

EC 2023-228

Identifier Type: -

Identifier Source: org_study_id